Addex Therapeutics Posts Q2 Profit Following Loss Last Year

In a recent report, Addex Therapeutics Ltd. showcased a significant turnaround with a second-quarter net profit of 12.88 million Swiss francs, contrasting with a loss in the previous year. Despite challenges in continuing operations, the overall financial performance exhibits potential optimism for investors.

Date: 30-09-2024

AI Rating: 6

The report outlines several key financial metrics for Addex Therapeutics Ltd. (ADXN) that can influence investor sentiment and stock prices.

Net Income: The company reported a second-quarter net profit of 12.88 million Swiss francs, a significant improvement from a net loss of 2.68 million francs in the same period last year. This turnaround could positively impact stock prices as it indicates a shift towards profitability.
Earnings Per Share (EPS): The net profit per share reached 0.08 franc, compared to a net loss per share of 0.04 franc from the previous year. Increasing earnings per share can be a positive indicator for investors, often leading to stock price appreciation.
Continuing Operations: The company recorded a net loss of 1.46 million francs from continuing operations, which is wider than last year's loss of 521 thousand francs. This is a negative aspect and may cause concern among investors regarding operational sustainability.
Operating Loss: Total operating loss also widened to 899 thousand francs from a loss of 396 thousand francs last year. This raises questions about operational efficiency and may negatively affect investor confidence.
Income for the Period: Income for the current period fell to 115 thousand francs, down from 632 thousand francs last year. This decline may suggest issues in revenue generation that could be detrimental to the investment outlook.

Overall, the report showcases both strong improvements in net income and EPS, but also highlights concerns regarding continuing operations and income decline, which could balance the overall optimistic view investors may have about Addex Therapeutics.

Stocks: ADXN